Consensus Sunshine Biopharma, Inc.

Equities

SBFM

US8677816014

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
0.8925 ^USD	-2.25%		+6.25%	-96.71%

Apr. 19	Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product	MT
Apr. 19	Top Premarket Decliners	MT

Evolution of the average Target Price on Sunshine Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b6de6788035ab4c4d73cecda7a8de9.XRVPjGkFUYIW7YupfTjTXSoRKyNvNkIs7p2uhhFrUVg.aiY14j5dZtB1hr-ZGFmHGmV6Z1lfXyoa3Kn59F4dAG0WdyTvMEgGtH2X0g~53d8bd808bc1887797358a141144e33f

Analyst Recommendations on Sunshine Biopharma, Inc.

Aegis Capital Initiates Sunshine Biopharma at Buy Rating With $2.60

23-08-07

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8925 USD

Average target price

15 USD

Spread / Average Target

+1,580.67%

High Price Target

15 USD

Spread / Highest target

+1,580.67%

Low Price Target

15 USD

Spread / Lowest Target

+1,580.67%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sunshine Biopharma, Inc.

Aegis Capital

Ratings for Sunshine Biopharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar